MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Phase 2
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: BIIL 284 BS low dose
Drug: Placebo
Drug: BIIL 284 BS medium dose
Drug: BIIL 284 BS high dose
First Posted Date
2014-09-29
Last Posted Date
2014-09-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
404
Registration Number
NCT02251210

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

First Posted Date
2014-09-29
Last Posted Date
2014-09-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
208
Registration Number
NCT02251223

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
657
Registration Number
NCT02248220

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

Phase 2
Terminated
Conditions
Alzheimer Disease
Interventions
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
198
Registration Number
NCT02248116

Antihypertensive Medications and the Risk of Sepsis

Completed
Conditions
Hypertension
Interventions
Drug: Other angiotensin-receptor blockers (ARBs)
Drug: Angiotensin-converting enzyme inhibitors (ACEIs)
Drug: Other major antihypertensive medication classes
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1129062
Registration Number
NCT02248896

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4255
Registration Number
NCT02248129

Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02249117

Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
442
Registration Number
NCT02248181

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-09-25
Last Posted Date
2024-04-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
25
Registration Number
NCT02248259
Locations
🇰🇷

1289.23.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type

Phase 2
Terminated
Conditions
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2014-09-25
Last Posted Date
2014-09-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
54
Registration Number
NCT02249351
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy